Sign in Subscribe

dmmr

A collection of 120 issues

Severe immune-related side effects studied in 1,175 MSI-H digestive cancer patients on immunotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Severe immune-related side effects studied in 1,175 MSI-H digestive cancer patients on immunotherapy An international study of 1,175 patients from 34 centers examined how grade 3 or higher immune-related adverse events correlate with progression-free survival and overall survival in

RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC A meta-analysis found that oncogenic driver mutations like RAS and BRAF may contribute to clinically meaningful differences in how MSI-H/dMMR metastatic colorectal cancer responds to immune checkpoint inhibitors,

MSI-H/dMMR Prevalence Documented in Japanese CRC Registry

Skip to content The CRC Digest MSI-H/dMMR Prevalence Documented in Japanese CRC Registry A multicenter study of 1,464 Japanese patients with primary colorectal cancer enrolled from April 2024 to March 2025 investigated the frequency and features of MSI-H/dMMR tumors to support personalized treatment strategies. (Annals of Gastroenterological

First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer A meta-analysis of phase III trials confirms immune checkpoint inhibitors show superior progression-free and overall survival compared to standard chemotherapy as first-line treatment for patients with MSI-H or dMMR metastatic disease. (J

CRC Research Update — July 20, 2026

Today's colorectal cancer research highlights

CRC Research Update — July 19, 2026

Today's colorectal cancer research highlights

Single-section PMS2/MSH6 double immunohistochemistry shows promise as screening tool for mismatch repair deficiency

Skip to content The CRC Digest ◇ RESEARCH Single-section PMS2/MSH6 double immunohistochemistry shows promise as screening tool for mismatch repair deficiency A study of 794 colorectal and endometrial cancer cases evaluated whether a single-section test could accurately identify deficient mismatch repair (dMMR) status. (Human Pathology) This content is informational only

DR5/Ligase 3 feedback loop drives immunogenicity in dMMR/MSI CRC

Skip to content The CRC Digest DR5/Ligase 3 feedback loop drives immunogenicity in dMMR/MSI CRC Preclinical study investigated why dMMR/MSI colorectal cancers are intrinsically immunogenic and why some do not respond or develop resistance to immune checkpoint inhibitors. (Gastroenterology) This content is informational only and does not

CRC Research Update — July 16, 2026

Today's colorectal cancer research highlights

Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC

Skip to content The CRC Digest Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC Comprehensive review discusses the immunological basis for exceptional responsiveness to PD-1 and CTLA-4 inhibitors in dMMR-MSI-H colorectal cancer, along with emerging resistance mechanisms and predictive biomarkers. (Front Immunol) This content is informational only and does not